---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-057620"
form_type: "8-K"
ticker: null
cik: "0001783032"
company_name: "Elevation Oncology, Inc."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:24:20.611706+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Elevation Oncology to be acquired by Concentra for $0.36/share plus CVR; CEO Ferra out

## Summary
- Merger with Concentra Biosciences: $0.36 cash per share plus contingent value right (CVR) for up to 80% of net proceeds from EO-1022.
- Board unanimously recommends tender; closing requires minimum $26.4M net cash and tender of >50% of outstanding shares.
- CEO Joseph Ferra terminated effective June 30; CFO Tammy Furlong appointed President and Interim CEO, receives $600K transaction bonus at closing.
- Stockholders approved reverse stock split (1:10–1:50), ratified auditor CohnReznick, and elected three Class I directors.
- Tang Capital Partners provides limited guaranty up to $21.4M; support agreements covering ~5.1% of shares secured.

## SEC filing metadata
- accession: 0001104659-25-057620
- form_type: 8-K
- cik: 0001783032
- company_name: Elevation Oncology, Inc.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/0001104659-25-057620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/tm2517439d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-057620
- JSON: https://secwatch.observer/filing/0001104659-25-057620.json
- Plain text: https://secwatch.observer/filing/0001104659-25-057620.txt

## Key facts
- Executive change
  Tammy Furlong was appointed as President and Interim Chief Executive Officer at Elevation Oncology, Inc..
  - Action: appointed
  - Role: President and Interim Chief Executive Officer
  source text: Effective as of the Separation Date, the Board appointed Tammy Furlong, age 54, the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, to succeed Mr. Ferra as President and Interim Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/0001104659-25-057620-index.htm
- Executive change
  Joseph J. Ferra, Jr. was terminated as President, Chief Executive Officer at Elevation Oncology, Inc..
  - Action: terminated
  - Role: President, Chief Executive Officer
  source text: In connection with the Merger, the Company terminated the employment of Joseph J. Ferra, Jr., as the Company’s President, Chief Executive Officer, effective as of June 30, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/0001104659-25-057620-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.